What types of Hepatitis C does Mavyret treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on June 13, 2025.

Official Answer by Drugs.com

Mavyret (glecaprevir and pibrentasvir) is an oral treatment for all hepatitis C virus (HCV) genotypes (1-6) in adult and pediatric patients 3 years and older.

Mavyret is FDA-approved for the treatment of adult and pediatric patients 3 years and older with:

acute or chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

Hepatitis C is a viral disease that causes inflammation of the liver. Over time it can lead to diminished liver function or liver failure. There are at least six distinct HCV genotypes, or strains, which are genetically distinct groups of the virus.

In Americans who have HCV:

Approximately 75 percent have genotype 1;
20-25 percent have genotypes 2 or 3;
and a small number of patients are infected with genotypes 4, 5 or 6.

Mavyret is used to treat all six genotypes of HCV. Other medicines that are used to treat all six genotypes of HCV include:

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) for the treatment of HCV in adults
Epclusa (sofosbuvir and velpatasvir) for the treatment of HCV in adults and children 3 years of age and older.

Mavyret oral tablets and oral pellets are taken once daily with food for a treatment duration of between 8 and 16 weeks.

What is the difference between hepatitis B and C?

Some of the main differences between hepatitis B and C are:

Hepatitis B virus can be prevented with a vaccine, but not hepatitis C.
Hepatitis B and C are different viruses, but you can have both hepatitis B and hepatitis C at the same time.
Over 90% of people infected with hepatitis C who have not received treatment can be cured with 8 to 12 weeks of oral medications, but treatment for hepatitis B, if needed, may be long-term or lifelong.
There is no cure for hepatitis B, but once you recover from acute hepatitis B, you develop antibodies that protect you from the virus for life.

What are the new drugs for the treatment of hepatitis C?

The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir). All are FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), as well as other uses. In June 2025, Mavyret was approved for the treatment of acute HCV.

How much does Mavyret cost?

The cost of Mavyret for 84 tablets is $14,101 if you are paying cash using the Drugs.com online discount card, however, most people do not pay this amount. If you have commercial insurance, AbbVie offers a $5 per month Copay Savings Card for eligible patients.

What types of Hepatitis C does Mavyret treat?

Read next

What is the difference between hepatitis B and C?

What are the new drugs for the treatment of hepatitis C?

How much does Mavyret cost?

See also:

Aimovig

Nurtec ODT

Botox

Depakote

Topamax

Emgality

Timolol

Valproic acid

Divalproex sodium

Topiramate

Related medical questions

Drug information

Related support groups